AVONCares Offers Aid to Underserved Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

NEW YORK-Cancer Care, Inc. has established a new program-The AVONCares Program for Medically Underserved Women-through a generous gift from The Avon Products Foundation. The program will provide financial assistance and relevant education and support to low-income, underinsured and uninsured, underserved women throughout the country in need of diagnostic and/or related services for the treatment of breast, cervical, and ovarian cancers.

NEW YORK—Cancer Care, Inc. has established a new program—The AVONCares Program for Medically Underserved Women—through a generous gift from The Avon Products Foundation. The program will provide financial assistance and relevant education and support to low-income, underinsured and uninsured, underserved women throughout the country in need of diagnostic and/or related services for the treatment of breast, cervical, and ovarian cancers.

The AVONCares Program will allow Cancer Care to provide financial assistance to help women pay for:

Diagnostic (postscreening) services that lead to definitive diagnoses for women who have had breast, cervical, and ovarian cancer screenings.

Transportation to and from treatment.

Childcare for women with families.

An escort to accompany older women to and from diagnostic workup and treatment.

Services offered to women through the AVONCares program will be accessible nationwide through Cancer Care’s toll-free line 1-800-813-HOPE (4673), via the Internet (www.cancercare.org), and at Cancer Care offices in the New York metropolitan area, New Jersey, and Connecticut.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.